The Role of Inflammatory Proteins in Anti-Glucocorticoid Therapy for Treatment-Resistant Depression
Background: Optimising treatments for patients with treatment-resistant depression (TRD) is key to reducing the burden of this severe illness. The anti-glucocorticoid medication metyrapone has mixed evidence supporting a role as a possible augmentation treatment in TRD. The degree of treatment resis...
Main Authors: | Rebecca Strawbridge, Alzbeta Jamieson, John Hodsoll, Ian Nicol Ferrier, Richard Hamish McAllister-Williams, Timothy R. Powell, Allan H. Young, Anthony J. Cleare, Stuart Watson |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/4/784 |
Similar Items
-
Randomised controlled trial of Antiglucocorticoid augmentation (metyrapone) of antiDepressants in Depression (ADD Study)
by: I Nicol Ferrier, et al.
Published: (2015-06-01) -
Metyrapone Treatment Protects Low-Density Lipoprotein Receptor Knockout Mice against Hypercorticosteronemia Development without Changing Atherosclerosis Susceptibility
by: Ronald J. van der Sluis, et al.
Published: (2023-08-01) -
Partial protection from organophosphate-induced cholinesterase inhibition by metyrapone treatment
by: Radosław Świercz, et al.
Published: (2013-08-01) -
Editorial: Adrenal insufficiency: Diagnostic approaches, treatments and outcomes
by: A. Pazderska, et al.
Published: (2023-04-01) -
Cushing Disease Treated Successfully With Metyrapone During Pregnancy
by: Ilana Ramer Bass, MD, MPH, et al.
Published: (2022-03-01)